R&D channel feed

J&J touts suc­cess of Vyv­gart com­peti­tor in two au­toim­mune dis­ease tri­als, in­clud­ing key myas­the­nia gravis study

Last year

Pli­ant’s chron­ic liv­er dis­ease drug has con­sis­tent safe­ty across dose ranges, PhII da­ta show

Last year

Am­gen en­ters weight loss mar­ket with drug that shows 14.5% weight re­duc­tion

Last year

4D Mol­e­c­u­lar Ther­a­peu­tic­s' gene ther­a­py cuts Eylea use in wet AMD pa­tients, biotech di­vulges plans for piv­otal stud­ies

Last year
Cell/Gene Tx

Re­al Hu­mi­ra com­pe­ti­tion may not ar­rive un­til 2026, Ab­b­Vie ex­ecs tell in­vestors

Last year
Pharma

Re­gen­eron aims to stop mus­cle loss with com­bi­na­tion treat­ment ap­proach in obe­si­ty

Last year
Pharma

Take­da says farewell to CFO, suite of clin­i­cal-stage pro­grams in Q3 up­date

Last year
Pharma

Schrödinger takes a step for­ward with Al­phaFold in drug R&D, as biotech hits a pipeline 'in­flec­tion'

Last year
AI

‘120 pages of da­ta’: Roche’s pipeline re­view leads to as­set cuts, but al­so ad­di­tions

Last year
Pharma

‘Watch this evolve’: Sanofi con­tin­ues to talk up its R&D bet as Paul Hud­son wel­comes new CFO

Last year
Pharma

Apoc­a­lypse or rip­ple? Ahead of first of­fers on price, new re­search pre­dicts IRA im­pact on R&D will be mod­est

Last year
FDA+

Bio­gen to halt sales and de­vel­op­ment of con­tro­ver­sial Alzheimer's drug Aduhelm

Last year
Pharma

Up­dat­ed: No­var­tis ax­es blood can­cer drug af­ter PhI­II flop, cau­tions on obe­si­ty FO­MO

Last year
Pharma

Gilead in­vests an­oth­er $320M in Ar­cus as part­ners re­hash their TIG­IT pact

Last year
Deals
Pharma

Ex­clu­sive: Jnana says piv­otal tri­al of PKU pill could be­gin next year af­ter promis­ing re­sults from a small­er study

Last year

Ver­tex’s pain drug suc­ceeds in late-stage stud­ies, mark­ing ma­jor break­through in search for new, non-opi­oid med­i­cines

Last year

FDA sched­ules March ODAC for Geron's MDS drug fol­low­ing PhI­II da­ta

Last year
FDA+

Sarep­ta shares PhII da­ta for next-gen ex­on skip­ping drug, but reg­u­la­to­ry path­way is un­clear

Last year

Roche ends KRAS deal with Hookipa Phar­ma, as biotech lays off 30% of staff

Last year
People
Deals

Bris­tol My­er­s' Op­di­vo fails part two of post-kid­ney can­cer surgery test as com­peti­tor Mer­ck touts new sur­vival da­ta

Last year
Pharma

First-ever RNA edit­ing tri­al in US gets clear­ance, pit­ting ‘ex­on edit­ing’ tech­nol­o­gy against vi­sion loss

Last year

Bio­phar­ma in­dus­try's vac­cine pipeline lacks ‘depth,' with an overem­pha­sis on Covid — re­port

Last year
Coronavirus

Mer­ck de­tails win for Keytru­da in blad­der can­cer af­ter surgery

Last year

Ex­clu­sive: Strand lays off 18% of staff as its first mR­NA ther­a­pies head in­to the clin­ic

Last year
People
First page Previous page 53545556575859 Next page Last page
A service from the Financial Times